Progress in treatment of multiple system atrophy
10.3969/j.issn.1004-1648.2023.06.022
- VernacularTitle:多系统萎缩治疗研究进展
- Author:
Han ZHANG
1
;
Nannan LI
;
Xinning ZHANG
Author Information
1. 100029 北京中医药大学第二临床医学院
- Keywords:
multiple system atrophy;
targeted therapy;
α-synuclein;
research progress
- From:
Journal of Clinical Neurology
2023;36(6):474-479
- CountryChina
- Language:Chinese
-
Abstract:
Multiple system atrophy(MSA)is an adult-onset and progressive neurodegenerative disease,is clinically classified into two subtypes:MSA with predominant parkinsonism(MSA-P)and MSA with predominant cerebellar ataxia(MSA-C),characterized by dysautonomia and dyskinesia.The etiology of MSA is still unknown,multiple pathogenic factors are involved in the pathogenesis of this disease,therefore,in addition to limited symptomatic treatment,there is still a lack of disease modifying therapy to prevent the progress of the disease.Currently,animal and clinical studies targeting α-synuclein,neuroinflammation and neurotrophic supporting are being explored,so this article reviewed the latest progresses to improve the clinical understanding of treatment of MSA.
